Alnylam PharmaceuticalsALNY
About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Employees: 2,100
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
72% more capital invested
Capital invested by funds: $16.9B [Q1] → $29.1B (+$12.2B) [Q2]
43% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 61
17% more call options, than puts
Call options by funds: $703M | Put options by funds: $600M
16% more repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 164
5% more funds holding
Funds holding: 488 [Q1] → 514 (+26) [Q2]
4.93% more ownership
Funds ownership: 89.87% [Q1] → 94.8% (+4.93%) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 8 [Q1] → 6 (-2) [Q2]
Research analyst outlook
25 Wall Street Analysts provided 1 year price targets over the past 3 months
25 analyst ratings
TD Cowen Ritu Baral 40% 1-year accuracy 2 / 5 met price target | 27%upside $371 | Buy Maintained | 21 Oct 2024 |
HC Wainwright & Co. Patrick Trucchio 39% 1-year accuracy 46 / 118 met price target | 37%upside $400 | Buy Reiterated | 18 Oct 2024 |
Scotiabank Greg Harrison 70% 1-year accuracy 14 / 20 met price target | 4%upside $305 | Sector Outperform Initiated | 16 Oct 2024 |
B of A Securities Tazeen Ahmad 54% 1-year accuracy 14 / 26 met price target | 7%upside $314 | Buy Maintained | 14 Oct 2024 |
Chardan Capital Keay Nakae 54% 1-year accuracy 22 / 41 met price target | 2%upside $300 | Buy Maintained | 11 Oct 2024 |
Financial journalist opinion
Based on 10 articles about ALNY published over the past 30 days
